HC Wainwright Analysts Boost Earnings Estimates for LifeMD

LifeMD, Inc. (NASDAQ:LFMD) – Equities researchers at HC Wainwright raised their Q4 2027 earnings estimates for LifeMD in a research note issued on Friday, August 7th. HC Wainwright analyst Y. Chen now expects that the company will post earnings per share of $0.17 for the quarter, up from their prior forecast of $0.15. HC Wainwright currently has a “Buy” rating and a $9.00 price target on the stock. The consensus estimate for LifeMD’s current full-year earnings is ($0.37) per share.

Other research analysts also recently issued reports about the company. Weiss Ratings reiterated a “sell (d)” rating on shares of LifeMD in a report on Tuesday, August 4th. BTIG Research cut their target price on LifeMD from $10.00 to $9.00 and set a “buy” rating on the stock in a research note on Thursday, August 6th. KeyCorp set a $5.00 price target on LifeMD and gave the stock an “overweight” rating in a research report on Friday, August 7th. Wall Street Zen cut shares of LifeMD from a “hold” rating to a “sell” rating in a research note on Saturday, July 18th. Finally, Zacks Research downgraded shares of LifeMD from a “hold” rating to a “strong sell” rating in a report on Friday, July 17th. Eight research analysts have rated the stock with a Buy rating and two have given a Sell rating to the company’s stock. According to data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus price target of $7.57.

LifeMD Price Performance

Shares of LifeMD stock opened at $3.46 on Friday. The firm has a market cap of $166.77 million, a price-to-earnings ratio of -69.19 and a beta of 2.02. The stock’s 50-day moving average is $4.29 and its 200-day moving average is $3.97. LifeMD has a one year low of $2.56 and a one year high of $7.32.

LifeMD (NASDAQ:LFMD) last announced its earnings results on Wednesday, August 5th. The company reported ($0.16) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.15) by ($0.01). LifeMD had a negative return on equity of 168.23% and a net margin of 0.10%.The company had revenue of $47.28 million during the quarter, compared to analyst estimates of $49.16 million.

Institutional Inflows and Outflows

A number of hedge funds have recently bought and sold shares of LFMD. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. raised its stake in shares of LifeMD by 4.7% during the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 49,647 shares of the company’s stock worth $270,000 after purchasing an additional 2,235 shares in the last quarter. Creative Planning acquired a new stake in shares of LifeMD in the 2nd quarter valued at approximately $272,000. JPMorgan Chase & Co. grew its stake in shares of LifeMD by 581.2% in the second quarter. JPMorgan Chase & Co. now owns 412,571 shares of the company’s stock valued at $5,619,000 after buying an additional 352,004 shares in the last quarter. Legal & General Group Plc increased its holdings in LifeMD by 187.4% during the second quarter. Legal & General Group Plc now owns 10,144 shares of the company’s stock worth $138,000 after buying an additional 6,614 shares during the last quarter. Finally, Rhumbline Advisers increased its holdings in LifeMD by 8.7% during the second quarter. Rhumbline Advisers now owns 53,589 shares of the company’s stock worth $730,000 after buying an additional 4,281 shares during the last quarter. 35.52% of the stock is currently owned by institutional investors.

About LifeMD

LifeMD (NASDAQ: LFMD) is a U.S.-based telehealth company that delivers on-demand, membership-based virtual healthcare services. Through its digital platform and mobile applications, LifeMD connects patients with board-certified healthcare providers for diagnosis, treatment and ongoing management of a range of acute and chronic conditions. The company’s core offering centers on personalized care plans supported by prescription fulfillment, lab testing and prescription delivery services.

LifeMD’s service portfolio spans several specialty areas, including men’s health, hormonal therapy, weight management and primary care.